Last Price
0.458
Today's Change
+0.149 (48.22%)
Day's Change
0.432 - 0.96
Trading Volume
567,523,762
Exchange: NASDAQ Global Market NASDAQ Global Market
Currency: USD USD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Mr. Sanjeev Luther Mr. Sanjeev Luther
Full Time Employees: 8 8
IPO Date: 1991-08-29 1991-08-29
CIK: 0000748592 0000748592
ISIN: US1140822099 US1140822099
CUSIP: 114082209 114082209
Beta: 7.77 7.77
Last Dividend: 0.00 0.00
Dcf Diff: -0.19 -0.19
Dcf: 2.40 2.40
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.